D. Fukamachi, Y. Okumura, N. Matsumoto, et al., “Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease,” Journal of Interventional Cardiology 2022 (2022): 5905022, https://doi.org/10.1155/2022/5905022.

In the article, the authors have identified errors in Table 2, where in the final row, ‘Noncardiovascular’ should read ‘All Cause’. The correct Table 2 is shown as follows:

Table 2 
Primary and secondary endpoints, per study group.

Additionally, in Section 3.2. Clinical Outcomes, the following sentence should be corrected from:

“Two patients given edoxaban monotherapy and one given the combination therapy suffered a noncardiovascular death.”

To:

“Two patients given edoxaban monotherapy and one patient given the combination therapy suffered all-cause deaths (HR: 1.99; 95% CI: 0.18–21.9). Cardiovascular death, a secondary endpoint, occurred in one patient in the edoxaban monotherapy group. Noncardiovascular death occurred in one patient in both groups.”

We apologize for these errors.